Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasia Khizeva

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Biomedicines|December 30, 2025
Synaptic Changes in Mice Lacking Alpha- and Gamma-SynucleinsAnastasia M Krayushkina, Olga Morozova, Anastasia Khizeva, et al.
Journal of Molecular Neuroscience : MN|January 8, 2026
Retrospective Study of the Physiological and Molecular Features of the S-FUS (1-359) Mouse Transgenic Model with an ALS-like Phenotype: Lifespan, Body Weight Dynamics, Movement Disorders, and Dysregulation of the Dopaminergic SystemEvgeny Bronovitsky, Kirill Chaprov, Anastasia Khizeva, et al.
Biomedicines|October 29, 2025
Bolus MPTP Injection in Aged Mice to Mimic Parkinson Disease: Effects of Low-Dose Antioxidant Treatment with Fullerene (C<sub>60</sub>) and Fullerenol (C<sub>60</sub>(OH)<sub>24</sub>)Tatyana Strekalova, Alisa Burova, Anna Gorlova, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Biomedicines|December 30, 2025
Synaptic Changes in Mice Lacking Alpha- and Gamma-SynucleinsAnastasia M Krayushkina, Olga Morozova, Anastasia Khizeva, et al.
Journal of Molecular Neuroscience : MN|January 8, 2026
Retrospective Study of the Physiological and Molecular Features of the S-FUS (1-359) Mouse Transgenic Model with an ALS-like Phenotype: Lifespan, Body Weight Dynamics, Movement Disorders, and Dysregulation of the Dopaminergic SystemEvgeny Bronovitsky, Kirill Chaprov, Anastasia Khizeva, et al.
Biomedicines|October 29, 2025
Bolus MPTP Injection in Aged Mice to Mimic Parkinson Disease: Effects of Low-Dose Antioxidant Treatment with Fullerene (C<sub>60</sub>) and Fullerenol (C<sub>60</sub>(OH)<sub>24</sub>)Tatyana Strekalova, Alisa Burova, Anna Gorlova, et al.
Pageof 1